PureTech Health (PRTC) 6-K Current report (foreign)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of May, 2022

Commission File Number 001-39670

PURETECH HEALTH PLC

(Translation of registrant’s name into English)

6 Tide Street, Suite 400

Boston, Massachusetts 02210

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  ☒            Form 40-F  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On May 9, 2022, PureTech Health plc (LSE: PRTC, Nasdaq: PRTC) (the “Company”) announced the commencement of a $50 million share repurchase program (the “Program”) of its ordinary shares of one pence each (“Ordinary Shares”). The Company plans to execute the Program in two equal tranches. In respect of the first tranche, PureTech entered into an irrevocable non-discretionary instruction with Jefferies International Limited (“Jefferies”) in relation to the purchase by Jefferies of Ordinary Shares for an aggregate consideration (excluding expenses) of no greater than $25 million and the simultaneous on-sale of such Ordinary Shares by Jefferies to PureTech. Jefferies makes its trading decisions in relation to the Ordinary Shares independently of, and uninfluenced by, the Company. Purchases may continue during any close period to which the Company is subject. Any purchase of Ordinary Shares under the first tranche of the Program are carried out on the London Stock Exchange and any other UK recognized investment exchange which may be agreed, in accordance with pre-set parameters and in accordance with, and subject to limits, including those limits related to daily volume and price, prescribed by the Company’s general authority to repurchase Ordinary Shares granted by its shareholders at its most recent annual general meeting on May 27, 2021, Chapter 12 of the Financial Conduct Authority’s UK Listing Rules, Article 5(1) of Regulation (EU) No. 596/2014 (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018) and Commission Delegated Regulation (EU) 2016/1052 (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018). All Ordinary Shares repurchased under the Program will be held in treasury.

During the month ended May 31, 2022, the Company had the following daily purchases of its own Ordinary Shares under the Program through Jefferies:

Date	Ordinary Shares Repurchased		Volume Weighted Average Price Paid per Ordinary Share		Highest Price Paid		Lowest Price Paid
May 9, 2022		29,545		163.88p		170.20p		161.00p
May 10, 2022		43,836		162.46p		166.40p		157.40p
May 11, 2022		44,630		172.17p		175.80p		167.00p
May 12, 2022		46,379		169.35p		173.20p		166.20p
May 13, 2022		21,361		174.64p		174.80p		172.80p
May 16, 2022		47,323		175.29p		176.40p		173.40p
May 17, 2022		46,037		177.35p		179.20p		174.20p
May 18, 2022		47,109		179.57p		181.00p		177.20p
May 19, 2022		46,603		175.29p		180.00p		171.00p
May 20, 2022		50,363		183.11p		185.20p		179.40p
May 23, 2022		50,950		184.49p		185.80p		181.40p
May 24, 2022		50,056		176.67p		183.00p		172.20p
May 25, 2022		49,379		175.03p		177.00p		170.00p
May 26, 2022		47,160		178.84p		180.20p		173.80p
May 27, 2022		47,919		180.78p		185.00p		177.80p
May 30, 2022		25,217		185.17p		186.00p		183.80p
May 31, 2022		49,249		184.70p		186.60p		179.00p

During the month ended May 31, 2022, the Company repurchased an aggregate of 743,116 Ordinary Shares. As of May 31, 2022, the Company’s issued share capital was 288,611,120 shares, 743,116 of which were held in treasury, resulting in total voting rights in the Company of 287,868,004 shares. To view the details of the individual transactions, please paste the following URL(s) into the address bar of your browser with respect to each individual date of repurchase under the Program:

May 9, 2022: https://data.fca.org.uk/artefacts/NSM/RNS/4363881.html

May 10, 2022: https://data.fca.org.uk/artefacts/NSM/RNS/4365501.html

May 11, 2022: https://data.fca.org.uk/artefacts/NSM/RNS/4367138.html

May 12, 2022: https://data.fca.org.uk/artefacts/NSM/RNS/4368852.html

May 13, 2022: https://data.fca.org.uk/artefacts/NSM/RNS/4370531.html

May 16, 2022: https://data.fca.org.uk/artefacts/NSM/RNS/4372195.html

May 17, 2022: https://data.fca.org.uk/artefacts/NSM/RNS/4373834.html

May 18, 2022: https://data.fca.org.uk/artefacts/NSM/RNS/4375570.html

May 19, 2022: https://data.fca.org.uk/artefacts/NSM/RNS/4377110.html

May 20, 2022: https://data.fca.org.uk/artefacts/NSM/RNS/4378718.html

May 23, 2022: https://data.fca.org.uk/artefacts/NSM/RNS/4380434.html

May 24, 2022: https://data.fca.org.uk/artefacts/NSM/RNS/4382153.html

May 25, 2022: https://data.fca.org.uk/artefacts/NSM/RNS/4383727.html

May 26, 2022: https://data.fca.org.uk/artefacts/NSM/RNS/4385273.html

May 27, 2022: https://data.fca.org.uk/artefacts/NSM/RNS/4386847.html

May 30, 2022: https://data.fca.org.uk/artefacts/NSM/RNS/4388273.html

May 31, 2022: https://data.fca.org.uk/artefacts/NSM/RNS/4390083.html

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	PURETECH HEALTH PLC
Date: June 3, 2022	By:	/s/ Daphne Zohar
		Name:	Daphne Zohar
		Title:	Chief Executive Officer